ARTICLE | Company News
FDA approves Opdivo for head and neck cancer
November 11, 2016 12:03 AM UTC
FDA approved an sBLA from Bristol-Myers Squibb Co. (NYSE:BMY) for Opdivo nivolumab to treat recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy.
The agency said it based the approval on data from the Phase III CheckMate -141 trial, in which Opdivo significantly improved overall survival compared with standard of care (see BioCentury Extra, April 19)...
BCIQ Company Profiles
BCIQ Target Profiles